指南与共识妇科肿瘤

新诊断晚期卵巢癌的新辅助化疗:ASCO指南更新

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
指南 / 共识 · J Clin Oncol · 2025-01-22

该ASCO指南更新基于61项研究,为III-IV期上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的新辅助化疗(NACT)与初次肿瘤细胞减灭术(PCS)选择提供推荐。指南强调由妇科肿瘤医生评估、诊断时提供胚系和体细胞检测,并根据手术适应性和完全细胞减灭可能性选择PCS或NACT。

要点

  • 疑似III-IV期上皮性卵巢癌应由妇科肿瘤医生评估,包括CA125、腹盆腔CT和胸部影像。
  • 适合手术且很可能实现完全细胞减灭者推荐PCS;适合手术但不太可能完全细胞减灭者推荐NACT。
  • NACT推荐铂-紫杉双药方案,化疗有反应或疾病稳定者应在≤4周期后行中间性肿瘤细胞减灭术(ICS)。

核心结论

  • 对适合手术且很可能实现完全细胞减灭的新诊断晚期上皮性卵巢癌患者推荐PCS,对适合手术但不太可能完全细胞减灭者推荐NACT。

研究设计与样本

  • 多学科专家小组召开会议并更新系统综述,61项研究构成证据基础。

主要发现

  • 证据基础由61项研究构成。

关键数值与推荐

  • 疑似III-IV期上皮性卵巢癌应由妇科肿瘤医生评估,评估包括癌抗原125、腹盆腔计算机断层扫描和胸部影像。
  • 所有上皮性卵巢癌患者应在诊断时接受胚系遗传和体细胞检测。
  • 对适合手术且很可能实现完全细胞减灭的新诊断晚期上皮性卵巢癌患者,推荐PCS。
  • 对适合PCS但被认为不太可能实现完全细胞减灭的患者,推荐NACT。
  • 新诊断晚期上皮性卵巢癌且围手术期风险高的患者应接受NACT。

临床怎么用

  • NACT前患者应有侵袭性卵巢癌的组织学确认。
  • NACT推荐铂-紫杉双药方案。
  • 对化疗有反应或疾病稳定的患者,应在≤4周期NACT后行ICS。
  • 对接受NACT的III期、体能状态良好且肾功能充足的患者,ICS期间可提供腹腔热灌注化疗。
  • ICS后化疗应继续完成6周期治疗计划,可选加用贝伐珠单抗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (epithelial ovarian cancer [EOC]). METHODS: A multidisciplinary Expert Panel convened and updated the systematic review. RESULTS: Sixty-one studies form the evidence base. RECOMMENDATIONS: Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All patients with EOC should be offered germline genetic and somatic testing at diagnosis. For patients with newly diagnosed advanced EOC who are fit for surgery and have a high likelihood of achieving complete cytoreduction, PCS is recommended. For patients fit for PCS but deemed unlikely to have complete cytoreduction, NACT is recommended. Patients with newly diagnosed advanced EOC and a high perioperative risk profile should receive NACT. Before NACT, patients should have histologic confirmation of invasive ovarian cancer. For NACT, a platinum-taxane doublet is recommended. Interval cytoreductive surgery (ICS) should be performed after ≤four cycles of NACT for patients with a response to chemotherapy or stable disease. For patients with stage III disease, good performance status, and adequate renal function treated with NACT, hyperthermic intraperitoneal chemotherapy may be offered during ICS. After ICS, chemotherapy should continue to complete a six-cycle treatment plan with the optional addition of bevacizumab. Patients with EOC should be offered US Food and Drug Administration-approved maintenance treatments. Patients with progressive disease on NACT should have diagnosis reconfirmed via tissue biopsy. Patients without previous comprehensive genetic or molecular profiling should be offered testing. Treatment options include alternative chemotherapy regimens, clinical trials, and/or initiation of end-of-life care.Additional information is available at www.asco.org/gynecologic-cancer-guidelines.This guideline has been endorsed by the Society of Gynecologic Oncology.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update. J Clin Oncol. 2025. PMID: 39841949. doi:10.1200/JCO-24-02589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。